when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ELI LILLY CO · news · pharmadog

← back to ELI LILLY CO

News mentioning ELI LILLY CO

630 stories

Sep 21, 26Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&Abiospace

Sep 21, 26Novo buys three early-stage obesity assets from Kallyope as investor pressure mountsbiospace

Sep 21, 26Novo struggles to appease restive investors with consumer plans, blockbuster ambitionsfiercebiotech

Sep 21, 26Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampedefiercebiotech

Sep 18, 26FDA approves Lilly's oral SERD combo for second-line breast cancer therapyendpoints

Sep 18, 26China plans to transform biotech sector into $522B powerhouse by 2030biospace

Sep 17, 26Novo partners with Orbis, deepening investment in oral peptide drugsbiopharma dive

Sep 17, 26Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugsbiospace

Sep 17, 26Chutes & Ladders—Legend poaches Novartis vet to boost commercial potentialfiercebiotech

Sep 17, 26Fed rate hike won’t hold biotech down despite climbing capital costsbiospace

Sep 17, 26Novartis drops $125M for Sironax’s tech to cross blood-brain barrierbiospace

Sep 17, 26DPHARM: How to address the clinical trial enrollment crisis?fiercebiotech

Sep 17, 26Lilly-backed Orbis does up to $1.4B macrocycle deal with Novoendpoints

Sep 17, 26North Immunology goes public via reverse merger as eczema drug heads toward clinicfiercebiotech

Sep 17, 26Trending: Top biopharma disciplines with jobs live nowbiospace

Sep 17, 26Biopharma hiring hotspots: States, disciplines where demand is highestbiospace

Sep 16, 26'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrandfiercebiotech

Sep 16, 26Novo looks to Anthropic’s AI models to ‘supercharge’ drug developmentbiopharma dive

Sep 16, 26Deep dive: Psychedelics back on FDA’s doorstepbiospace

Sep 16, 26Why a US senator wants a biotech leader in the White House who ‘has the president’s ear’fiercebiotech

Sep 16, 26Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotechfiercebiotech

Sep 15, 26FDA clears first generic radioligand drug; Sionna turns to layoffsbiopharma dive

Sep 15, 26Rocket's Danon plans; Novo leaves Ascendis; Lilly's latest dealendpoints

Sep 15, 26Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotechfiercebiotech

Sep 14, 26Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrandbiospace

Sep 14, 26AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger marketbiospace

Sep 14, 26Lilly cans early experimental obesity drug after ‘high bar’ not metfiercebiotech

Sep 14, 26Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptidefiercebiotech

Sep 14, 26Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofifiercebiotech

Sep 14, 26STAT+: What’s in a name? Novo looks to a rebrandstat

← prevpage 7 of 21next →